Showing results (51-60 of 135) with videos related to
Sort By:
Pageof 14
Health Affairs (Project Hope)|December 3, 2024
US Trends In Anticancer Medicine Pricing And The Impact Of Competition, 2014-20Rena M Conti, Claire Mcglave, Meredith B Rosenthal, et al.Pediatrics|March 5, 2020
Pediatric Orphan Drug Indications: 2010-2018Lauren Kimmel, Rena M Conti, Anna Volerman, et al.Health Affairs (Project Hope)|May 9, 2007
Authorized generic drugs, price competition, and consumers' welfareErnst R Berndt, Richard Mortimer, Ashoke Bhattacharjya, et al.Health Affairs (Project Hope)|September 9, 2016
Has The Era Of Slow Growth For Prescription Drug Spending Ended?Murray Aitken, Ernst R Berndt, David Cutler, et al.Journal of Health Economics|January 10, 2015
The heterogeneity of concentrated prescribing behavior: Theory and evidence from antipsychoticsErnst R Berndt, Robert S Gibbons, Anton Kolotilin, et al.Journal of Managed Care & Specialty Pharmacy|August 2, 2021
The cost-effectiveness of therapeutic drug monitoring for the prescription drug-based treatment of chronic myeloid leukemiaRena M Conti, William V Padula, Russell V Becker, et al.The Milbank Quarterly|January 29, 2024
Assessing the Impact of the 340B Drug Pricing Program: A Scoping Review of the Empirical, Peer-Reviewed LiteratureTimothy W Levengood, Rena M Conti, Sean Cahill, et al.JAMA Pediatrics|December 17, 2019
Association of Opioid Prescribing Patterns With Prescription Opioid Overdose in Adolescents and Young AdultsKao-Ping Chua, Chad M Brummett, Rena M Conti, et al.The Lancet. Oncology|November 8, 2016
21st century pharmacovigilance: efforts, roles, and responsibilitiesPeter J Pitts, Hervé Le Louet, Yola Moride, et al.The Quarterly Review of Economics and Finance : Journal of the Midwest Economics Association|August 22, 2007
QUALITY-CONSTANT "PRICES" FOR THE ONGOING TREATMENT OF SCHIZOPHRENIA: AN EXPLORATORY STUDY*Richard G Frank, Ernst R Berndt, Alisa B Busch, et al.Pageof 14